Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5865 Articles

Chris Lange | Aug 17, 2015 at 9:45 AM EDT

Is AVEO the Next Aquinox for Traders?

Aveo Pharmaceuticals made waves in early trading indications Monday on news of a licensing agreement with Novartis.

Jon C. Ogg | Aug 16, 2015 at 9:10 AM EDT

Credit Suisse Sees Big Biopharma Upside in Top Contract Research Outfits

Credit Suisse assumed coverage with handy upside in the CRO leaders, and on average the firm is calling for upside…

Chris Lange | Aug 14, 2015 at 1:45 PM EDT

Why Onconova Is on the Move

Onconova Therapeutics has announced the submission of an investigational new drug application to the FDA.

Chris Lange | Aug 14, 2015 at 11:45 AM EDT

Aquinox Pharma Continues to Impress Investors

Aquinox Pharmaceuticals has made an absolutely ridiculous run in the past week alone, proving that it is a day trader’s…

Lee Jackson | Aug 13, 2015 at 9:20 AM EDT

JPMorgan Has Favorite Biotech Stocks to Buy for Rest of 2015

In a new research report, JPMorgan highlights its favorite biotech stocks to buy after the second-quarter earnings print.

Jon C. Ogg | Aug 12, 2015 at 5:14 PM EDT

Why the FDA Extended Review Date on Key Melanoma Drug Opdivo

Bristol-Myers Squibb announced that the FDA has now extended the action date for the supplemental biologics license application for Opdivo…

Paul Ausick | Aug 12, 2015 at 1:55 PM EDT

Big First-Day Pop for Global Blood Therapeutics IPO

A biopharmaceutical company working on developing and commercializing treatments for serious blood-based disorders priced its initial public offering (IPO) above…

Chris Lange | Aug 12, 2015 at 1:05 PM EDT

Can Eleven Bio Get Back to Even With This Study?

Eleven Biotherapeutics was at the top of the list for gainers in the market Wednesday. This move comes on an…

Chris Lange | Aug 12, 2015 at 9:45 AM EDT

Short Sellers Back Off Big Pharma

The short interest data have been released for the July 31 settlement date, and for most of the selected pharmaceutical…

Chris Lange | Aug 12, 2015 at 8:55 AM EDT

Short Sellers Run for Cover From Major Biotechs

The short interest data are out for the July 31 settlement date, and overall, short interest in the selected biotech…

Jon C. Ogg | Aug 12, 2015 at 7:35 AM EDT

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

It may be impossible to ever know if a true bottom has ever been seen, but many investors love finding…

Chris Lange | Aug 11, 2015 at 1:35 PM EDT

How to Value This Rally in Novavax Shares

Despite the market falling on Tuesday, Novavax bucked the trend and was up handily, after a Phase 2 breakthrough with…

Lee Jackson | Aug 11, 2015 at 10:35 AM EDT

UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio

A new research report from UBS makes an interesting switch in the Quality Growth At a Reasonable Price (Q-GARP) portfolio.

Jon C. Ogg | Aug 10, 2015 at 3:19 PM EDT

Why AbbVie Should Be Worth 25% More

Independent research firm Argus has maintained its Buy rating and its $85.00 price target on AbbVie.

Jon C. Ogg | Aug 10, 2015 at 2:22 PM EDT

Is Cannabis Biotech Zynerba the Hottest Post-IPO of 2015?

ThinkstockZynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) had a solid run on Monday following the prior week’s initial public offering. The problem…

1 … 250 251 252 253 254 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Is AVEO the Next Aquinox for Traders?

Credit Suisse Sees Big Biopharma Upside in Top Contract Research Outfits

Why Onconova Is on the Move

Aquinox Pharma Continues to Impress Investors

JPMorgan Has Favorite Biotech Stocks to Buy for Rest of 2015

Why the FDA Extended Review Date on Key Melanoma Drug Opdivo

Big First-Day Pop for Global Blood Therapeutics IPO

Can Eleven Bio Get Back to Even With This Study?

Short Sellers Back Off Big Pharma

Short Sellers Run for Cover From Major Biotechs

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

How to Value This Rally in Novavax Shares

UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio

Why AbbVie Should Be Worth 25% More

Is Cannabis Biotech Zynerba the Hottest Post-IPO of 2015?

The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

Why SpaceX Is About to Spend Billions on Something It Can’t Launch

Emerging Markets Are Embarrassing the S&P 500: EEM Up 28% YTD

The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year

Forget VOO: Fidelity’s Tech ETF Is Up 29% While the Broad Market Lags

The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

Health and Healthcare Articles

All Health and Healthcare Articles

Is AVEO the Next Aquinox for Traders?

Credit Suisse Sees Big Biopharma Upside in Top Contract Research Outfits

Why Onconova Is on the Move

Aquinox Pharma Continues to Impress Investors

JPMorgan Has Favorite Biotech Stocks to Buy for Rest of 2015

Why the FDA Extended Review Date on Key Melanoma Drug Opdivo

Big First-Day Pop for Global Blood Therapeutics IPO

Can Eleven Bio Get Back to Even With This Study?

Short Sellers Back Off Big Pharma

Short Sellers Run for Cover From Major Biotechs

5 Top BioPharma Stocks That May Have Sold Off Too Much and Become Bargains

How to Value This Rally in Novavax Shares

UBS Makes Big Changes to Quality Growth at a Reasonable Price Portfolio

Why AbbVie Should Be Worth 25% More

Is Cannabis Biotech Zynerba the Hottest Post-IPO of 2015?

The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

Why SpaceX Is About to Spend Billions on Something It Can’t Launch

Emerging Markets Are Embarrassing the S&P 500: EEM Up 28% YTD

Featured Reads

The Dividend Growth Path That Hauls in a Bigger Paycheck Than Your HR Rep

The 401(k) Bracket Smoothing Math: Why a 66 Year Old Couple With $1.5 Million Should Convert Exactly $90,000 a Year